白塞综合征总体损害指数(BODI)用于回顾性研究的验证及修改建议
研究纳入300例至少两次间隔1年就诊的白塞综合征患者,评估BODI在回顾性数据中的结构效度、信度和可行性。回顾性与面对面评估BODI相关性好(ICC 0.99),观察者间和观察者内一致性良好(ICC 0.96和1)。BODI未捕获的主要损害条目包括高血压、肝衰竭、肺实质受累、青光眼和淋巴水肿。
要点
- 回顾性与面对面评估BODI相关性好(ICC 0.99;95%CI 0.99-0.99)。
- 观察者间和观察者内一致性良好(ICC 0.96和1)。
- BODI未捕获高血压、肝衰竭、肺实质受累、青光眼和淋巴水肿。
核心结论
- BODI似乎是一种可靠且可行的工具,可用于回顾性研究中的损害评估。
- 使用本研究中识别的额外损害条目修改BODI可能使其成为更好的量表。
研究设计与样本
- 纳入300例至少两次间隔1年就诊的白塞综合征患者。
- 通过比较从患者病历和面对面访视计算的BODI评分评估回顾性试验的结构效度。
- 由两名不同观察者和同一观察者间隔六个月以盲法使用回顾性病历数据评分BODI。
- 评估填写BODI的时间以评价可行性,并识别BODI遗漏的损害条目。
主要发现
- 回顾性与面对面评估BODI之间相关性好(ICC 0.99;95%CI 0.99-0.99)。
- 观察者间和观察者内一致性良好(ICC分别为0.96和1)。
- BODI未捕获的主要损害条目为高血压、肝衰竭、肺实质受累、青光眼和淋巴水肿。
关键数值与推荐
- 回顾性与面对面评估BODI的ICC为0.99(95%CI 0.99-0.99)。
- 观察者间ICC为0.96,观察者内ICC为1。
- BODI未捕获的损害条目包括高血压、肝衰竭、肺实质受累、青光眼和淋巴水肿。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Assessment of damage accrual over time is important for evaluating and comparing long-term results of treatment modalities and strategies. Retrospective studies may be useful for assessing long-term damage, especially in rare diseases. We aimed to validate Behçet's Syndrome Overall Damage Index (BODI) for use in retrospective studies by evaluating its construct validity, reliability and feasibility in retrospectively collected data. Additionally, we aimed to determine missing items by evaluating Behçet's syndrome patients with different types of organ involvement and long-term follow-up. METHODS: We included 300 patients who had at least two clinic visits at 1-year intervals. The construct validity for use in retrospective trials was assessed by comparing BODI scores calculated from patient charts and during face-to-face visits. BODI was additionally scored using retrospective chart data by two different observers and by the same observer six months apart, in a blinded manner. The time for filling BODI was evaluated to assess feasibility. Additionally, damaged items that were missing from BODI were identified. RESULTS: There was a good correlation between the retrospective and face-to-face evaluation of BODI (ICC 0.99; %95 CI 0.99-0.99). Inter-observer and intra-observer agreement were good (ICC 0.96 and 1, respectively). The main damage items that BODI did not capture were hypertension, liver failure, lung parenchymal involvement, glaucoma and lymphedema. CONCLUSION: BODI seems to be a reliable and feasible instrument for assessing damage in retrospective studies. Modifying BODI using the additional damage items identified in this study may make it an even better scale.
引用
- Ozogul YY, Ozguler Y, Esatoglu SN, et al. Validation of the Behçet's Syndrome Overall Damage Index (BODI) for retrospective studies and a proposal for modification. Rheumatology (Oxford). 2025. PMID: 38733594. doi:10.1093/rheumatology/keae266
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。